Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) --Nasus Pharma Ltd.(NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products,todayannouncedthatupcomingdataforNS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA,February 27toMarch2.

“We are excited to share data highlighting NS002’s potential for superior epinephrine absorption and robust formulation stability,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Designed as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore thepotentialadvantages ofthe powder technology.We believe NS002representsaunique and potentially superiordifferentiated epinephrine delivery option for the treatment of anaphylaxis, where seconds truly matter.”

Presentation details:

About Nasus PharmaNasus Pharma is a clinical-stage pharmaceutical company developinga number ofintranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visitwww.nasuspharma.comor follow onTwitter (X)orLinkedIn.

Forward Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, NasusPharmais using forward looking statements in this press release when it discusses:the potential of NS002for superior epinephrine absorption;its aim to deliver epinephrine more rapidly in emergency situations;and the belief that NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectusdated August 12,2025filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.